FDA grants breakthrough status to new Hodgkin's lymphoma therapy

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Adcetris (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin's lymphoma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news